课题基金 / 基金详情

iPSC-derived cardiomyocytes to model estrogen receptor modulation of stress cardiomyopathy and arrhythmic syndromes

iPSC-derived cardiomyocytes to model estrogen receptor modulation of stress cardiomyopathy and arrhythmic syndromes
iPSC 衍生的心肌细胞模拟应激性心肌病和心律失常综合征的雌激素受体调节
批准号:
MR/M010422/1
负责人:
Sian Harding
金额:
$43.78万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2015
资助国家:
英国
项目状态:
已结题
起止时间:
2015 至 --

项目摘要

项目成果

Sian Harding的其他基金

相似基金

相关文献

中文摘要
翻译
人们早就知道,与男性相比,年轻女性相对更容易患心脏病。对于心律失常引起的猝死,男性受影响的可能性要高出80%。这通常发生在突然或慢性压力之后,由肾上腺素引发。我们一直在研究一种新描述的综合征,在这种综合征中,突然的极度休克(事故、丧亲)不会导致猝死,而是导致心脏功能暂时下降,然后逆转。患者来医院时以为自己心脏病发作,但在几天到几周内恢复正常的心脏功能。有趣的是,80 - 90%的患者是更年期前后的女性。我们在麻醉的大鼠模型中重现了这一点,并表明单剂量的肾上腺素可以产生相同的效果。(In事实上,一剂肾上腺素从epi笔有时可以有相同的结果在人)。我们发现,非常高的肾上腺素可以通过影响心脏细胞表面的受体,从兴奋性转变为兴奋性。当我们试图阻止它对心脏功能的影响时,我们诱发了心脏性猝死。我们的想法是,高肾上腺素通过受体转换从刺激性(但具有破坏性)转变为刺激性(但具有保护性),这可以防止猝死。在这里,我们想知道为什么这种情况在雌激素下降的时候尤其发生在女性身上,以及这是否能让我们深入了解男性/女性的差异。对于这些实验,我们想从动物模型转向人类多能干细胞(hPSC)。我们知道hPSC可以可靠地转化为跳动的心脏细胞(hPSC-CM),并且它们可以表现出与它们来自的患者相同的中断节律。它们的肾上腺素受体更像人类,而不是动物,肾上腺素可以在培养皿中产生与整个心脏相同的节律效应。它们在培养中也非常持久,并且可以更容易地进行实验-例如关闭和打开特定的蛋白质。我们已经有方法来测量它们的跳动活动以及它们被损坏的容易程度。我们也有许多hPSC细胞系,反映了人类群体中不同的天然基因变异。我们的目标是发现肾上腺素开关的机制以及它如何被女性激素改变。对我们来说,理想的目标是找到一种方法来利用这种保护作用,而不产生暂时的心脏功能丧失,并开发一种药物来使用这种机制。hPSC-CM的另一个优点是它们可以大量生产并同时用于多种测定。同样的细胞和方法现在被制药公司用来测试药物,这意味着我们任何有希望的发现都可以更快地进入药物开发。
英文摘要
It has long been known that young women are relatively protected from heart disease compared to men. For sudden death arising from disrupted heart rhythm, men are 80% more likely to be affected. This often occurs after sudden or chronic stress, and is triggered by adrenaline. We have been studying a newly described syndrome in which a sudden extreme shock (accident, bereavement) produces not sudden death, but a temporary reduction in heart function which then reverses. Sufferers come in to hospital thinking they are having a heart attack, but recover within days to weeks to have normal heart function. Interestingly, 80-90% of sufferers are women around or after the menopause. We reproduced this in an anesthetised rat model, and showed that a single dose of adrenaline could give the same effect. (In fact one dose of adrenaline from an epi-pen can sometimes have the same result in people). We found that very high adrenaline could switch from being stimulant to depressant, through an effect on its receptors on the heart cell surface. When we tried to stop it being depressant on the heart function, we induced sudden cardiac death. Our idea is that high adrenaline goes from being stimulant (but damaging) to depressant (but protective) through a receptor switch, and that this protects against sudden death. Here we want to know why this happens particularly in women at a time when estrogen is dropping, and whether this can give us insights into male/female differences.For these experiments we want to move away from animal models to human pluripotent stem cells (hPSC). We know hPSC can reliably be turned into beating cardiac cells (hPSC-CM), and that they can show the same disrupted rhythm as a patient from which they came. They have adrenaline receptors more like human than are found in animal species, and adrenaline can produce the same kind of rhythm effects in the dish as in the whole heart. They are also very long-lasting in culture, and can be more easily experimented on - for example to turn off and on specific proteins. We already have ways to measure their beating activity and how easily they can be damaged. We also have a number of hPSC lines reflecting different natural gene variation in human populations. We aim to discover the mechanism of the adrenaline switch and how it can be changed by female hormones. The ideal goal for us would be to find a way to harness the protective effect without producing the temporary loss of heart function, and to develop a drug to use that mechanism. One other advantage of the hPSC-CM is that they can be produced in large quantities and used in multiple assays at the same time. The same cells and methods are being used now by pharmaceutical companies to test drugs, which means that any of our promising findings can go more quickly into drug development.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1093/cvr/cvab210
发表时间: 2022-06-22
期刊: Cardiovascular research
影响因子: 10.8
作者: []
通讯作者:
DOI: 10.1080/07853890.2020.1861644
发表时间: 2021-12
期刊: Annals of medicine
影响因子: 4.4
作者: [Adu-Amankwaah J, Mprah R, Adekunle AO, Ndzie Noah ML, Adzika GK, Machuki JO, Sun H]
通讯作者: Sun H
Reply to: Estrogens for protection from an index and recurrent episodes of takotsubo syndrome?
回复:雌激素可以预防章鱼壶综合症的指数和复发吗?
DOI: 10.1530/joe-21-0227
发表时间: 2021
期刊: The Journal of endocrinology
影响因子: --
作者: [Fu L]
通讯作者: Fu L
199 Takotsubo syndrome associated mir-16 and mir-26a reduce contractility of cardiomyocytes in vitro by an inhibitory g-?protein dependent mechanism
199 Takotsubo 综合征相关的 mir-16 和 mir-26a 通过抑制性 g-β 蛋白依赖性机制降低体外心肌细胞的收缩力
DOI: 10.1136/heartjnl-2017-311726.197
发表时间: 2017
期刊: Heart
影响因子: 5.7
作者: [Couch L]
通讯作者: Couch L
BHF Imperial Cardiovascular Regenerative Medicine Centre
  • 批准号:
    MR/L012618/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $91.05万
  • 财政年份:
    2013
  • 负责人:
    Sian Harding
  • 依托单位:
Stem cell-derived cardiomyocytes for detection of cardiotoxicity in cancer therapeutics
  • 批准号:
    G1000035/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $41.19万
  • 财政年份:
    2010
  • 负责人:
    Sian Harding
  • 依托单位:
An engineered heart patch from embryonic stem cells
  • 批准号:
    BB/D011027/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $61.64万
  • 财政年份:
    2006
  • 负责人:
    Sian Harding
  • 依托单位:
国内基金
海外基金
tRNA-derived small RNA上调YBX1/CCL5通路参与硼替佐米诱导慢性疼痛的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    张祥忠
  • 依托单位:
一类DMOA-Derived Meroterpenoid的全合成研究
  • 批准号:
    22071192
  • 项目类别:
    面上项目
  • 资助金额:
    63.0万元
  • 批准年份:
    2020
  • 负责人:
    胡向东
  • 依托单位:
TET1/exosome-derived miR-22-3p/BTG1信号轴在膀胱癌化疗耐药中的作用与分子机制
  • 批准号:
    82072807
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    肖峻
  • 依托单位:
基于寨卡病毒NS1和NS5的海洋微生物中抗病毒化合物的发现
  • 批准号:
    81973204
  • 项目类别:
    面上项目
  • 资助金额:
    56.0万元
  • 批准年份:
    2019
  • 负责人:
    宋福行
  • 依托单位: